Mineralys Therapeutics, Inc. (MLYS) This autumn 2025 Earnings Name March 12, 2026 4:30 PM EDT
Firm Contributors
Jon Congleton – President, CEO & Director
Adam Levy – CFO & Secretary
David Rodman – Chief Medical Officer
Eric Warren
Convention Name Contributors
Daniel Ferry – Lifesci Advisors, LLC
Michael DiFiore – Evercore ISI Institutional Equities, Analysis Division
Jin Regulation – Goldman Sachs Group, Inc., Analysis Division
Seamus Fernandez – Guggenheim Securities, LLC, Analysis Division
Jason Gerberry – BofA Securities, Analysis Division
Annabel Samimy – Stifel, Nicolaus & Firm, Included, Analysis Division
Mohit Bansal – Wells Fargo Securities, LLC, Analysis Division
Rami Katkhuda – LifeSci Capital, LLC, Analysis Division
Georgia Financial institution – Jefferies LLC, Analysis Division
Presentation
Operator
Greetings, and welcome to the Mineralys Therapeutics Fourth Quarter and Full Yr 2025 Convention Name. [Operator Instructions] Please word this convention is being recorded. I’ll now flip the convention over to your host, Dan Ferry of LifeSci Advisors. Please go forward.
Daniel Ferry
Lifesci Advisors, LLC
Thanks, operator. I want to welcome everybody becoming a member of us in the present day for our fourth quarter and full 12 months 2025 convention name. This afternoon, after the shut of market buying and selling, we issued a press launch offering our fourth quarter and full 12 months 2025 monetary outcomes and enterprise updates. A replay of in the present day’s name can be accessible on the Traders part of our web site roughly 1 hour after its completion. After our ready remarks, we’ll open the decision for Q&A.
Earlier than we start, I want to remind everybody that this convention name and webcast will comprise forward-looking statements concerning the firm. Precise outcomes might differ materially from these said or implied by these forward-looking statements resulting from dangers and uncertainties related to the corporate’s enterprise. These forward-looking statements are certified by the cautionary statements contained in in the present day’s press launch and our SEC filings, together with our annual report on Type 10-Ok
